BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31498836)

  • 21. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Lee JS; Rhee TM; Pietrasz D; Bachet JB; Laurent-Puig P; Kong SY; Takai E; Yachida S; Shibata T; Lee JW; Park HC; Zang DY; Jeon K; Lee J; Kim M; Kim HS; Kang HJ; Lee YK
    Sci Rep; 2019 Nov; 9(1):16971. PubMed ID: 31740696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.
    Ruess DA; Makowiec F; Chikhladze S; Sick O; Riediger H; Hopt UT; Wittel UA
    BMC Surg; 2015 Nov; 15():123. PubMed ID: 26615588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
    Karasek P; Gablo N; Hlavsa J; Kiss I; Vychytilova-Faltejskova P; Hermanova M; Kala Z; Slaby O; Prochazka V
    Cancer Genomics Proteomics; 2018; 15(4):321-327. PubMed ID: 29976637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
    Shi HJ; Jin C; Fu DL
    World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer.
    Boone BA; Sabbaghian S; Zenati M; Marsh JW; Moser AJ; Zureikat AH; Singhi AD; Zeh HJ; Krasinskas AM
    J Surg Oncol; 2014 Aug; 110(2):171-5. PubMed ID: 24665063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma.
    Xu J; Shi KQ; Chen BC; Huang ZP; Lu FY; Zhou MT
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1394-1402. PubMed ID: 27973703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis.
    Sharma G; Whang EE; Ruan DT; Ito H
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1229-37. PubMed ID: 26152276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Second-look operation in pancreatic carcinoma previously assessed as unresectable].
    Warnick P; Bahra M; Andreou A; Neuhaus P; Glanemann M
    Zentralbl Chir; 2010 Feb; 135(1):70-4. PubMed ID: 20162503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative C-reactive protein to albumin ratio is a predictor of survival after pancreatic resection for pancreatic ductal adenocarcinoma.
    Ikuta S; Aihara T; Yamanaka N
    Asia Pac J Clin Oncol; 2019 Oct; 15(5):e109-e114. PubMed ID: 30632282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel Physiobiological Parameter-Based Grading System for Resectable Pancreatic Cancer.
    Okabayashi T; Shima Y; Sumiyoshi T; Sui K; Iwata J; Morita S; Shimada Y; Iiyama T
    Ann Surg Oncol; 2018 Jul; 25(7):1889-1895. PubMed ID: 29691738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma.
    Wang F; Gill AJ; Neale M; Puttaswamy V; Gananadha S; Pavlakis N; Clarke S; Hugh TJ; Samra JS
    Ann Surg Oncol; 2014 Jun; 21(6):1937-47. PubMed ID: 24558067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of centralization on long-term survival after resection of pancreatic ductal adenocarcinoma.
    Ahola R; Siiki A; Vasama K; Vornanen M; Sand J; Laukkarinen J
    Br J Surg; 2017 Oct; 104(11):1532-1538. PubMed ID: 28517236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
    Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
    Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma.
    Moon HJ; An JY; Heo JS; Choi SH; Joh JW; Kim YI
    Pancreas; 2006 Jan; 32(1):37-43. PubMed ID: 16340742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes.
    Gilabert M; Turrini O; Ewald J; Moureau-Zabotto L; Poizat F; Raoul JL; Delpero JR
    Surg Oncol; 2018 Dec; 27(4):619-624. PubMed ID: 30449481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.